Fulcrum Therapeutics (FULC) Net Cash Flow (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Net Cash Flow data on file, last reported at -$147.3 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$147.3 million, down 818.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.1 million (up 262.63% YoY), and the FY2025 annual result was $139.3 million, up 325.3% from the prior year.
• Net Cash Flow declined to -$147.3 million in Q1 2026 per FULC's latest filing, from $150.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $150.5 million in Q4 2025 and troughed at -$147.3 million in Q1 2026.
• A 5-year average of $879882.4 and a median of -$768000.0 in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2026: Net Cash Flow jumped 6189.58% in 2024, then sank 818.5% in 2026.
• A 5-year view of Net Cash Flow shows it stood at -$55.8 million in 2022, then jumped by 91.91% to -$4.5 million in 2023, then tumbled by 219.19% to -$14.4 million in 2024, then soared by 1143.52% to $150.5 million in 2025, then tumbled by 197.88% to -$147.3 million in 2026.
• Business Quant data shows FULC's Net Cash Flow at -$147.3 million in Q1 2026, $150.5 million in Q4 2025, and $4.5 million in Q3 2025.